Amy Thompson[email protected]AITop 5 predictions for the imaging IT and AI markets in 2025Amy Thompson of Signify Research shares five predictions for the Imaging IT and AI markets in a new column.January 15, 2025PACS/VNAEnterprise imaging: What is the market opportunity beyond radiology?Amy Thompson of Signify Research assesses the future prospects for the enterprise imaging market.October 18, 2023PACS/VNAImaging IT market entering an atypical growth periodA new analysis by U.K. market insights firm Signify Research finds the global imaging IT market has recovered swiftly from the slight downturn experienced in 2020. Driving the growth is spending on tools that aid in COVID-19 care delivery.May 26, 2022Page 1 of 1Top StoriesMolecular ImagingSPECT/CT MPI may guide medical therapy in CAD patientsSPECT/CT myocardial perfusion imaging can identify patients with coronary artery disease who are more likely to benefit from specific therapies.MRIAI model uses MRI data to predict brain cancer patient survivalWomens ImagingUltrafast breast MRI's advantages may need to be reconsideredMolecular ImagingPET/MRI and DECT show abnormalities in long COVID patientsUltrasoundARRS: Cancer status should be considered for axillary breast ultrasound
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
